The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist), published in 2014, was the first major study designed to evaluate spironolactone’s efficacy in patients with HFpEF and HFmrEF using a mineralocorticoid receptor antagonist approach [6]. The gene discussed is NR3C2; the disease is heart failure.